Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence
Authors
Keywords
-
Journal
INFECTION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-03
DOI
10.1007/s15010-020-01557-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
- (2020) Roujian Lu et al. LANCET
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- First Case of 2019 Novel Coronavirus in the United States
- (2020) Michelle L. Holshue et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
- (2020) Kimiyasu Shiraki et al. PHARMACOLOGY & THERAPEUTICS
- Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
- (2020) Emmie de Wit et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit
- (2020) Duxin Sun AAPS Journal
- Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
- (2020) Eli S. Rosenberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
- (2020) Safiya Richardson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary
- (2020) Mohamed A. Hendaus JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
- (2020) Dandan Wu et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
- (2020) Ivan Fan-Ngai Hung et al. LANCET
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
- (2020) Yeming Wang et al. LANCET
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
- (2020) Jason D. Goldman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
- (2020) Joshua Geleris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Compassionate Use of Remdesivir for Patients with Severe Covid-19
- (2020) Jonathan Grein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effective treatment of severe COVID-19 patients with tocilizumab
- (2020) Xiaoling Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome
- (2020) Frank L van de Veerdonk et al. eLife
- Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
- (2020) Ling Li et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Early safety indicators of COVID-19 convalescent plasma in 5000 patients
- (2020) Michael J. Joyner et al. JOURNAL OF CLINICAL INVESTIGATION
- Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
- (2020) Alexandre B. Cavalcanti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status
- (2020) Spinello Antinori et al. PHARMACOLOGICAL RESEARCH
- Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline
- (2020) Muhammad Abbas Abid et al. Frontiers in Immunology
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
- (2020) Christoph D. Spinner et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial
- (2020) Remo H M Furtado et al. LANCET
- Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study
- (2020) Sean T. H. Liu et al. NATURE MEDICINE
- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
- (2020) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
- (2020) Anup Agarwal et al. BMJ-British Medical Journal
- Ebola virus disease
- (2019) Denis Malvy et al. LANCET
- A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
- (2019) Sabue Mulangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
- (2018) Maria L. Agostini et al. mBio
- Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
- (2017) Yousuke FURUTA et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
- (2017) Timothy P. Sheahan et al. Science Translational Medicine
- Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea
- (2016) PLOS MEDICINE
- Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults
- (2015) Yuji Kumagai et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Dose regimen of favipiravir for Ebola virus disease
- (2015) France Mentré et al. LANCET INFECTIOUS DISEASES
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started